Jubilant Therapeutics announced that preliminary Phase 1 clinical data for its novel drug candidate, JBI-802, will be presented orally at the 68th American Society of Hematology (ASH) Annual Meeting. JBI-802 is a first-in-class oral dual LSD1/HDAC6 inhibitor being evaluated for Essential Thrombocythemia (ET) and related myeloproliferative neoplasms (MPNs). Early findings show encouraging results, including rapid platelet reductions and durable hematologic control in treated patients.
Jubilant Therapeutics Presents Promising Data for JBI-802 at ASH Meeting
Jubilant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing precision therapeutics for myeloproliferative neoplasms (MPNs), has announced the selection of its preliminary Phase 1/2 study data for JBI-802 for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting is scheduled to take place from December 12-15, 2026, in New Orleans and online.
JBI-802 is a first-in-class, orally administered dual inhibitor of LSD1 and HDAC6 (CoREST). The abstract data presented at ASH showcases encouraging early evidence of rapid platelet reductions and hematologic control in patients with ET and related MPNs. Jubilant Therapeutics expressed optimism regarding the potential of JBI-802 to address unmet needs in these patient populations.
Key Findings from Preliminary Data
Key findings from the abstract, based on data collected as of June 30, 2026, indicate:
- All 8 patients who initiated treatment at the 15 mg dose achieved a >50% platelet reduction or normalization (<400 ×109/L) by Week 3, with a median time to response of 15 days.
- Platelet normalization was maintained for up to 33, 44, and 46 weeks in patients who received 15 mg and had more than 12 weeks of follow-up.
- Seven out of 11 patients with leukocytosis at the 15 mg dose achieved a complete hematologic response.
- No dose-limiting toxicities were observed at the tested doses of 5, 7, or 15 mg.
Additional efficacy, safety, and molecular data will be shared during the oral session.
About the Presentations
The oral presentation, titled “Safety and preliminary efficacy results from a Phase 1/2 multicenter open-label study evaluating JBI-802, a first-in-class oral CoREST inhibitor, in myeloproliferative and myelodysplastic/myeloproliferative neoplasms,” will be delivered by Andrew McQuillan, MBBS, FRACP, FRCPA. A poster presentation will cover “Pharmacokinetics, active-metabolite contribution, and pharmacokinetic/pharmacodynamic correlation of JBI-802, a first-in-class oral dual LSD1/HDAC6 (CoREST) inhibitor, in patients with MPN and MDS/MPN,” presented by Sridharan Rajagopal, Ph.D.
Scientific and Corporate Event
Jubilant Therapeutics will host a scientific and corporate event on December 14, 2026, following the oral presentation. This event, titled “Dual LSD1/HDAC6 Inhibition with JBI-802 in Thrombocytosis-Predominant MPN: Clinical Data and Emerging Perspectives,” will provide a review of the Phase 1 data presented at ASH and discuss its clinical implications. The event will be livestreamed, with a replay available on the company’s website.
About JBI-802 and Jubilant Therapeutics
JBI-802 is an orally administered dual inhibitor targeting the CoREST complex, designed to address multiple disease-relevant processes in myeloproliferative neoplasms. Jubilant Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small-molecule medicines for significant unmet medical needs, particularly in the area of MPNs.
Source: BSE
